Triple-Negative Breast Cancer (TNBC) is the most aggressive type of breast malignancy, with chemotherapy as the only mainstay treatment. TNBC patients have the worst prognoses as a large fraction of them do not achieve complete pathological response post-treatment and develop drug-resistant residual...
To investigate the biological function of circPSMA1 in breast cancer cells, loss-of-function and gain-of-function assays were performed. The qRT-PCR results showed the circPSMA1 overexpression or knockdown efficiency of transfection with the circPSMA1 overexpression or RNAi vector (Fig. 2A, B);...
Understanding the intricate signaling network involved in triple-negative breast cancer (TNBC) represents a challenge for developing novel therapeutic approaches. Here, we aim to provide novel mechanistic insights on the function of the S100A8/A9-RAGE system in TNBC. Methods TNM plot analyzer, Kaplan...
Triple-negative breast cancer (TNBC) cells’ secretome can induce a pro-inflammatory phenotype in human adipose-derived mesenchymal stem cells (hADMSC). This can be prevented by the green tea polyphenol epigallocatechin-3-gallate (EGCG). The impact of EGCG on the paracrine regulation that the ext...
Phosphorylation proteomics is the basis for the study of abnormally activated kinase signaling pathways in breast cancer, which facilitates the discovery of new oncogenic agents and drives the discovery of potential targets for early diagnosis and therapy of breast cancer. In this study, we have explo...
Moreover, EIF6-224aa directly interacted with MYH9, an oncogene in breast cancer, and decreased MYH9 degradation by inhibiting the ubiquitin-proteasome pathway and subsequently activating the Wnt/beta-catenin pathway. Our study provided novel insights into the roles of protein-coding circRNAs and ...
点击文末“阅读原文/Read more”,即可访问Journal of Hematology & Oncology官网阅读完整论文。 参考资料 [1] Yun Li et al. Recent advances in therapeutic strategies for triple-negative breast cancer. Journal of Hematology & Oncology. Doi: 10.1186/s13045-022-01341-0...
[1]Taylor M, Reddy S, Kumar PA, et al. Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC). 2024 ASCO. 1092. [2]Dai LJ, Ma D, Xu YZ, et al. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast...
Schmid P, Jung KH, Wysocki PJ, et al. Datopotamab deruxtecan + durvalumab as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II study. Ann Oncol. 2022;33(suppl 3):S199. doi:10.1016/j.an...
3. Shao ZM, et al. Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial. 2024 SABCS. Abstract GS3-06. 4.待补充 5. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for earl...